Prediction of an Optimal Dose of Aripiprazole in the Treatment of Schizophrenia From Plasma Concentrations of Aripiprazole Plus Its Active Metabolite Dehydroaripiprazole at Week 1

@article{Nagai2017PredictionOA,
  title={Prediction of an Optimal Dose of Aripiprazole in the Treatment of Schizophrenia From Plasma Concentrations of Aripiprazole Plus Its Active Metabolite Dehydroaripiprazole at Week 1},
  author={G. Nagai and K. Mihara and A. Nakamura and K. Nemoto and S. Kagawa and T. Suzuki and T. Kondo},
  journal={Therapeutic Drug Monitoring},
  year={2017},
  volume={39},
  pages={62–65}
}
Background: It has been suggested that a plasma trough concentration of aripiprazole plus its active metabolite, dehydroaripiprazole of 225 ng/mL is a threshold for a good therapeutic response in the treatment of acutely exacerbated patients with schizophrenia. The present study investigated whether or not an optimal dose of aripiprazole could be predicted from these concentrations at week 1. Methods: The subjects were 26 inpatients with schizophrenia, who received aripiprazole once a day for 3… Expand
DDDT_A_290963 463..479
  • Yingjie Qi, Guangxuan Liu
  • 2021
Department of Pharmacy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, 110042, Liaoning Province, People’s Republic of China Purpose: We developed andExpand
Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry for Simultaneous Determination of Antipsychotic Drugs in Human Plasma and Its Application in Therapeutic Drug Monitoring
TLDR
An ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous therapeutic drug monitoring (TDM) and clinical pharmacokinetic antipsychotic drugs and ISs was developed and validated, providing significant information to support future clinical TDM and rational drug use research. Expand
Aripiprazole Cytotoxicity Coincides with Activation of the Unfolded Protein Response in Human Hepatic Cells
TLDR
This study reveals for the first time a cytotoxic effect of Aripiprazole that involves the induction of ER stress and IRE1 activation, mechanisms involved in diet-induced obesity. Expand
Correction to “Aripiprazole Cytotoxicity Coincides with Activation of the Unfolded Protein Response in Human Hepatic Cells”
TLDR
This study reveals for the first time a cytotoxic effect of Aripiprazole that involves the induction of ER stress and IRE1 activation, mechanisms involved in diet-induced obesity. Expand

References

SHOWING 1-10 OF 23 REFERENCES
Effects of Paroxetine on Plasma Concentrations of Aripiprazole and Its Active Metabolite, Dehydroaripiprazole, in Japanese Patients With Schizophrenia
TLDR
This study suggests that lower doses (10–20 mg/d) of paroxetine coadministration increase plasma concentrations of aripiprazole and the sum of a Ripiprazol and its active metabolite, dehydroaripipiprazoles, and dehydroAripipazole were unchanged throughout the study period. Expand
Effects of escitalopram on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients.
TLDR
The present study suggests that low doses of escitalopram can be safely coadministered with aripiprazole, at least from a pharmacokinetic point of view. Expand
Lack of Correlation Between the Steady-State Plasma Concentrations of Aripiprazole and Haloperidol in Japanese Patients With Schizophrenia
TLDR
The correlations between the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripipazole, and those of haloperidol in 19 Japanese patients with schizophrenia are suggested to be non-significant, because of the greater involvement of CYP2D6 in the metabolism of a Ripiprazoles than in that of hal operidol. Expand
Pharmacokinetic and Pharmacodynamic Interactions Between Carbamazepine and Aripiprazole in Patients With Schizophrenia
TLDR
The present study implies that carbamazepine augmentation may be effective for patients with schizophrenia treated with aripiprazole, although carbazepine dramatically decreases plasma concentrations of aripIPrazole and dehydroaripipipazole, by inducing the metabolism of these compounds. Expand
Effects of the CYP2D6*10 Allele on the Steady-State Plasma Concentrations of Aripiprazole and Its Active Metabolite, Dehydroaripiprazole, in Japanese Patients With Schizophrenia
TLDR
It is suggested that the CYP2D6*10(*10) allele plays an important role in controlling the steady-state plasma concentrations of aripiprazole and the sum of a Ripiprazoles and dehydroaripiprazol in Asian subjects. Expand
Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects
TLDR
It seems likely that therapeutic drug monitoring can be helpful to improve the antipsychotic drug therapy, as serum levels of aripiprazole and dehydroaripiprazoles were highly variable between individuals and distinct ranges were associated with good therapeutic response and minimal side effects. Expand
Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE.
TLDR
The urinary 6beta-hydroxycortisol/ cortisol concentration ratio following ITz administration for 7 consecutive days was about half of that before the start of ITZ administration, indicating that CYP3A4 metabolic activity was inhibited by administration of ITz. Expand
Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
TLDR
Evidence suggests that its efficacy in the treatment of the positive and negative symptoms of schizophrenia and its lower propensity for extrapyramidal symptoms (EPS) may be attributable to aripiprazole's partial agonist activity at dopamine D2 receptors. Expand
Effects of Genetic Polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the Steady-State Plasma Concentrations of Aripiprazole and Its Active Metabolite, Dehydroaripiprazole, in Japanese Patients With Schizophrenia
TLDR
The findings of this study suggest that CYP2D6 genotypes play an important role in controlling steady-state plasma concentrations of aripiprazole and the sum of a Ripiprazoles and dehydroaripiprazol in Asian subjects, whereas CYP3A5 and ABCB1 genotypes seemed unlikely to have an impact. Expand
Improvement in antipsychotic-induced hyperprolactinemia with the addition of aripiprazole in schizophrenic patients
Purpose: Hyperprolactinemia, a common adverse effect of antipsychotics, frequently impacts patients' quality of life. Aripiprazole is a potent dopamine D2 receptor partial agonist and rarelyExpand
...
1
2
3
...